Russian study to monitor Real-World use of acalabrutinib in CLL patients
NCT ID NCT04746950
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This observational study will follow about 90 adults with chronic lymphocytic leukemia (CLL) in Russia who are prescribed acalabrutinib as part of their routine care. Researchers will collect data from medical records to see how long patients stay free of disease progression and what side effects occur. No extra tests or treatments are involved—just watching what happens in real-world practice.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
acalabrutinib
What this could lead to
If successful, this study could provide real-world evidence on how well acalabrutinib works and its side effects in routine clinical practice for CLL patients in Russia.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by patient selection and local practices. It cannot prove cause and effect.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Ufa, Bashkortostan Republic, 450054, Russia
-
Research Site
Kaliningrad, Kaliningrad Oblast, Russia
-
Research Site
Khabarovsk, Khabarovskiy Kray, 680009, Russia
-
Research Site
Syktyvkar, Komi, Russia
-
Research Site
Krasnoyarsk, Krasnoyarsk Region, 660022, Russia
-
Research Site
Saint Petersburg, Leningradskaya Oblast', 198205, Russia
-
Research Site
Moscow, Moscow Oblast, 125284, Russia
-
Research Site
Moscow, Moscow Oblast, 129110, Russia
-
Research Site
Nizhny Novgorod, Nizhny Novgorod Oblast, Russia
-
Research Site
Novosibirsk, Novosibirsk Oblast, 630091, Russia
-
Research Site
Yakutsk, Sakha Republic, 677008, Russia
-
Research Site
Saratov, Saratov Oblast, 410028, Russia